Therapeutic effect of combined use of interferon alpha-1b, interleukin-2 and thalidomide on reversing minimal residual disease in acute myeloid leukemia.
10.3760/cma.j.issn.0253-2727.2019.02.004
- VernacularTitle:干扰素α-1b、白细胞介素2联合沙利度胺方案干预治疗微小残留病阳性急性髓系白血病的疗效分析
- Author:
Rui Hua MI
1
;
Lin CHEN
1
;
Xu Dong WEI
1
;
Qing Song YIN
1
;
Min Fang WANG
2
;
Li Jie LIANG
1
;
Fang Fang YUAN
1
;
Meng Juan LI
1
;
Xuan Jing JI
2
;
Yong Ping SONG
1
Author Information
1. The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou 450008, China.
2. Pingdingshan First People's Hospital, Pingdingshan 467000, China.
- Publication Type:Journal Article
- Keywords:
Interferon;
Interleukin-2;
Leukemia, myeloid;
Minimal residual disease;
Thalidomide
- MeSH:
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Flow Cytometry;
Humans;
Interferon-alpha;
Interleukin-2;
Leukemia, Myeloid, Acute/drug therapy*;
Neoplasm, Residual;
Prognosis;
Remission Induction;
Thalidomide
- From:
Chinese Journal of Hematology
2019;40(2):111-116
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the effect of combination regimen of interferon alpha-1b, interleukin-2 and thalidomide (ITI regimen) on minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) who were in hematologic remission but MRD-positive. Methods: Eighteen patients (17 from Tumor Hospital of Zhengzhou University and 1 from the First People's Hospital of Pingdingshan City) with AML admitted from July 2016 to June 2018, who were in hematologic remission but MRD-positive were treated with different doses of ITI regimen, and the MRD levels were monitored. Results: Among 18 patients who received a conventional dose of ITI regimen for 1 to 2 months, 7 patients had undetectable MRD, 3 had significant decrease in MRD levels, 3 had elevated MRD level and had hematologic recurrence. Three patients with elevated MRD level received a higher dose of ITI regimen, 2 of them turned to MRD negative and the other 1 patient had decreased MRD level. The total response rate was 72.2%, and the response rate in patients with MRD > 1.0% was 57.1% (4/7) , and that of patients with MRD < 1.0% was 81.8% (9/11) , respectively. Conclusion: The ITI regimen can reduce the MRD level of patient with AML who are in hematologic remission but MRD-positive. The therapeutic effect could be improved by a higher dose administration of ITI regimen, and therapeutic effect may be negatively correlated with MRD level before treatment.
